Last $115.22 USD
Change Today -5.23 / -4.34%
Volume 567.5K
GEVA On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/26/15 - $122.88
52 Week Low
09/22/14 - $60.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

synageva biopharma corp (GEVA) Related Bloomberg News

View More Bloomberg News

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL), which is under Phase III clinical trials for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy for lysosomal storage diseases, known as mucopolysaccharidosis type IIIB, as well as protein therapeutic programs for rare life-threatening diseases. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

172 Employees
Last Reported Date: 03/4/14
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $601.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $360.5K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $380.1K
Executive Vice President of Medical and Regul...
Total Annual Compensation: $379.6K
Senior Vice President of JAPAC & LATAM Commer...
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2013.

synageva biopharma corp (GEVA) Key Developments

Synageva BioPharma Announces Dosing Of Patients Commenced with SBC-103 In Phase 1/2 Study for Mucopolysaccharidosis IIIB

Synageva BioPharma Corp. announced dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) has begun as part of a Phase 1/2 study. In addition, the U.S. Food and Drug Administration (FDA) recently granted SBC-103 Fast Track designation. Fast Track is a process designed to facilitate development and expedite review of drugs to treat serious and life-threatening conditions and fill an unmet medical need to get important new drugs to patients expeditiously. The trial will enroll approximately nine patients, two years of age or greater but less than 12 years of age, with definitive diagnosis of MPS IIIB and developmental delay. Patients will be treated in one of three different dosing cohorts (0.3 mg/kg, 1.0 mg/kg or 3.0 mg/kg) with every other week intravenous administrations of SBC-103 for 24 weeks. Patients who meet qualifying criteria may continue therapy with SBC-103 for an extended treatment period that will last up to 128 weeks.

Synageva BioPharma Corp. Announces Sebelipase Alfa Marketing Authorization Application Validated by the EMA

Synageva BioPharma Corp. announced validation by the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for sebelipase alfa for LAL Deficiency. The EMA recently granted the company's request for accelerated assessment, which has the potential to shorten the EMA's regulatory review time. The MAA, and the Biologics License Application (BLA) submitted to the U.S. Food and Drug Administration (FDA), include previously reported data from the global, randomized, double-blind, placebo controlled Phase 3 trial of sebelipase alfa in children and adults with LAL Deficiency, and the Phase 2/3 trial of sebelipase alfa in infants with LAL Deficiency. Patients in these trials, combined with patients in other ongoing clinical trials with sebelipase alfa, represent the patient population studied to date for this rare, devastating disease. LAL Deficiency is a serious, underdiagnosed disease with significant morbidity and early mortality. LAL Deficiency causes progressive and multisystemic organ damage including hepatic cirrhosis and accelerated atherosclerosis that can lead to sudden and unpredictable clinical complications. LAL Deficiency often manifests in childhood but can be diagnosed at all ages with a simple blood test. LAL Deficiency is caused by genetic mutations that result in decreased LAL enzyme activity in the lysosomes across multiple body tissues, leading to the buildup of fatty material in the liver, blood vessel walls and other tissues. Sebelipase alfa is a recombinant form of the human LAL enzyme being developed by Synageva as an enzyme replacement therapy for LAL Deficiency. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa received fast track designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants.

Synageva BioPharma Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 09:00 AM

Synageva BioPharma Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 09:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Sanj K. Patel, Chief Executive Officer, President, Secretary and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $115.22 USD -5.23

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies

Industry Analysis


Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 437.9x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 430.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at